Key result
Machine learning methods successfully classified calcium transient signals from iPSC-CMs, identifying significant differences between control, symptomatic, and asymptomatic Brugada syndrome mutation carriers.
Why the study?
The study evaluated whether machine learning methods could classify calcium transient signals from iPSC-CMs to distinguish drug responses and detect phenotypic differences between symptomatic and asymptomatic Brugada syndrome mutation carriers.
Can machine learning methods classify calcium transient signals from iPSC-CMs to separate drug responses and differentiate between symptomatic and asymptomatic Brugada syndrome mutation carriers?
Can machine learning methods classify calcium transient signals from iPSC-CMs to separate drug responses and differentiate between symptomatic and asymptomatic Brugada syndrome mutation carriers?
Machine learning can effectively classify calcium transient signals in iPSC-CMs to distinguish drug responses and phenotypic differences in Brugada syndrome mutation carriers.
Should not yet change Brugada syndrome management; hypothesis-generating for ML phenotyping of iPSC-CM calcium signals.
Earlier it has been found that peak data of calcium transient signals originating from human induced pluripotent stem cell-derived cardiomyocytes are possible to be used to study how machine learning methods can be applied to separate which cells respond to a drug. Beating behavior of induced pluripotent stem cell derived cardiomyocytes (iPSC-CMs) from a symptomatic individual and an asymptomatic individual carrying a mutation for Brugada syndrome was analyzed with Ca 2+ imaging method. Using machine learning methods, it is studied whether it is possible to classify the current peak data successfully and whether differences in the two mutant cell lines could be observed. We applied more machine learning methods than before. Baseline signals were first recorded and they were then exposed to adrenaline and these to an antiarrhythmic drug flecainide which should provoke the disease phenotype. Calcium transient signals derived from induced pluripotent stem cell-derived cardiomyocytes were used for all computational analyses executed. Good classification results were generated with effective machine learning methods. Various test situations were applied to study how different parts of data can be separated to ensure their differences. Good results were gained that support the target so that it is possible to analyze whether the drug impacted on iPSC-CMs. It is also possible to separate which cells were affected by the drug and which were not affected. An important finding was that there were significant differences between calcium transient signals data originated from control subjects and patients and also between responses of the cells from symptomatic and asymptomatic individuals.
No takes yet. Share an insight, caveat, or question.
Juhola et al. (2025) studied Brugada syndrome. Adrenaline and flecainide exposure vs. Baseline signals / control subjects was evaluated on Classification of calcium transient signals and identification of drug effects and differences between cell lines. Machine learning methods successfully classified calcium transient signals from iPSC-CMs, identifying significant differences between control, symptomatic, and asymptomatic Brugada syndrome mutation carriers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: